Relationship of Endometrial Cancer and Serum Soluble L1CAM Level
Completed
- Conditions
- Endometrium Cancer
- Interventions
- Diagnostic Test: serum soluble L1CAM (sL1CAM)
- Registration Number
- NCT04603599
- Lead Sponsor
- Kocaeli University
- Brief Summary
The aim of this study is to evaluate the effect of serum soluble L1CAM (sL1CAM) on the diagnosis and prognosis of endometrial cancer. This prospective randomized controlled trial will be conducted in patients who have undergone endometrial biopsy and whose pathology results are reported as benign endometrial changes, endometrial hyperplasia, or endometrial cancer. The sL1CAM level between groups will be compared. The relationship between prognostic factors and serum sL1CAM will be evaluated in patients with endometrial cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 146
Inclusion Criteria
- Patients who underwent endometrial biopsy due to abnormal uterine bleeding and whose pathology results were reported as benign endometrial changes, endometrial hyperplasia or endometrial cancer were included in the study. All patients participating in the study signed informed consent.
Exclusion Criteria
- Patients who did not have consent, received neoadjuvant therapy and who would not have surgery despite endometrial cancer were excluded from the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description endometrial cancer serum soluble L1CAM (sL1CAM) - endometrial hyperplasia serum soluble L1CAM (sL1CAM) - benign endometrial changes serum soluble L1CAM (sL1CAM) -
- Primary Outcome Measures
Name Time Method serum sL1CAM level one year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Merve Demir
🇹🇷Kocaeli, Turkey